BIOMÉRIEUX: Strong Q3 but FY19 sales growth guidance lowered | NEUTRAL | EUR70
BIOMÉRIEUX - NEUTRAL | EUR70Strong Q3 but FY19 sales growth guidance lowered
Q3 growth ahead of CSS … but FY19 sales guidance lowered
Strong growth across the board
Immunoassays growth was a positive surprise
FY19 topline growth guidance lowered
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.